Abstract Churg–Strauss syndrome (CSS), alternatively known as eosinophilic
granulomatosis with polyangiitis (EGPA), was first described in 1951 by Churg and Strauss …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Eosinophilic lung diseases are a group of diffuse parenchymal lung diseases 1, 2
characterized by the prominent infiltration of the lung interstitium and the alveolar spaces by …

Summary Background Omalizumab (Xolair®) is a recombinant humanized monoclonal anti‐
IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent …

The precise pathogenetic mechanisms of Churg–Strauss syndrome are only partly
elucidated. Recent results suggest that antineutrophil cytoplasmic autoantibodies are …

Churg–Strauss angiitis or syndrome (CSA) is defined as an eosinophil-rich and
granulomatous inflammation involving the respiratory tract, and necrotising vasculitis …

Because of its practical and therapeutic repercussions, the priority remains the prompt,
relatively easy identification of the most severely affected patients at CSS diagnosis, before …

Objective To describe the efficacy and safety of omalizumab, an anti‐IgE monoclonal
antibody, in patients with refractory and/or relapsing eosinophilic granulomatosis with …

Background Churg-Strauss syndrome (CSS) is a rare systemic vasculitis associated with
asthma, eosinophilia, sinusitis, and pulmonary infiltrates. CSS has been reported in …

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has
been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing …